Phosphodiesterase 2 and Its Isoform a as Therapeutic Targets in the Central Nervous System Disorders
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Cyclic adenosine monophosphates (cAMP) and cyclic guanosine monophosphate (cGMP) are two essential second messengers, which are hydrolyzed by phosphodiesterase's (PDEs), such as PDE-2. Pharmacological inhibition of PDE-2 (PDE2A) in the central nervous system improves cAMP and cGMP signaling, which controls downstream proteins related to neuropsychiatric, neurodegenerative, and neurodevelopmental disorders. Considering that there are no specific treatments for these disorders, PDE-2 inhibitors' development has gained more attention in the recent decade. There is high demand for developing new-generation drugs targeting PDE2 for treating diseases in the central nervous and peripheral systems. This review summarizes the relationship between PDE-2 with neuropsychiatric, neurodegenerative, and neurodevelopmental disorders as well as its possible treatment, mainly involving inhibitors of PDE2.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
CNS & neurological disorders drug targets - (2023) vom: 25. Sept. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Metkar, Sanjay K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
And Neurodevelopmental disorders |
|---|
| Anmerkungen: |
Date Revised 10.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/1871527323666230811093126 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363477802 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363477802 | ||
| 003 | DE-627 | ||
| 005 | 20240210232750.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1871527323666230811093126 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1286.xml |
| 035 | |a (DE-627)NLM363477802 | ||
| 035 | |a (NLM)37855295 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Metkar, Sanjay K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Phosphodiesterase 2 and Its Isoform a as Therapeutic Targets in the Central Nervous System Disorders |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Cyclic adenosine monophosphates (cAMP) and cyclic guanosine monophosphate (cGMP) are two essential second messengers, which are hydrolyzed by phosphodiesterase's (PDEs), such as PDE-2. Pharmacological inhibition of PDE-2 (PDE2A) in the central nervous system improves cAMP and cGMP signaling, which controls downstream proteins related to neuropsychiatric, neurodegenerative, and neurodevelopmental disorders. Considering that there are no specific treatments for these disorders, PDE-2 inhibitors' development has gained more attention in the recent decade. There is high demand for developing new-generation drugs targeting PDE2 for treating diseases in the central nervous and peripheral systems. This review summarizes the relationship between PDE-2 with neuropsychiatric, neurodegenerative, and neurodevelopmental disorders as well as its possible treatment, mainly involving inhibitors of PDE2 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Neurodegenerative | |
| 650 | 4 | |a Neuropsychiatric | |
| 650 | 4 | |a Phosphodiesterase 2 (PDE2 or PDE2A) | |
| 650 | 4 | |a and Neurodevelopmental disorders | |
| 650 | 4 | |a cyclic AMP (cAMP) | |
| 650 | 4 | |a cyclic GMP (cGMP) | |
| 700 | 1 | |a Yan, Yuqing |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Yue |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Jianming |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Xiongwei |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Fu |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Ying |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t CNS & neurological disorders drug targets |d 2006 |g (2023) vom: 25. Sept. |w (DE-627)NLM161975518 |x 1996-3181 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:25 |g month:09 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871527323666230811093126 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 25 |c 09 | ||